ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.102,15
0,75%
S&P 500
5.930,85
1,09%
US Dollar vs BRL
6,086
0,00%
Bitcoin
96.334,28
-0,90%
Brent Oil
72,72
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Xeris Biopharma Holdings Inc (XERS)

  7. Xeris Biopharma Holdings Inc (XERS) Notícias

XERS

Xeris Biopharma (XERS)

Xeris Biopharma Holdings Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:XERS
DataHoraFonteTítuloCódigoCompanhia
26/11/202409:00Business WireXeris to Participate in Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
08/11/202418:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XERSXeris Biopharma Holdings Inc
08/11/202409:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
08/11/202409:00Business WireXeris Biopharma Reports Third Quarter 2024 Financial ResultsNASDAQ:XERSXeris Biopharma Holdings Inc
31/10/202409:00Business WireXeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
04/10/202417:05Business WireXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:XERSXeris Biopharma Holdings Inc
22/08/202408:00Business WireXeris to Participate in Upcoming Investor ConferencesNASDAQ:XERSXeris Biopharma Holdings Inc
09/08/202417:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
08/08/202417:27Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:XERSXeris Biopharma Holdings Inc
08/08/202408:00Business WireXeris Biopharma Reports Second Quarter 2024 Financial ResultsNASDAQ:XERSXeris Biopharma Holdings Inc
02/08/202418:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
25/07/202408:00Business WireXeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
08/07/202408:00Business WireXeris Biopharma Announces CEO Succession PlanNASDAQ:XERSXeris Biopharma Holdings Inc
03/06/202408:00Business WireXeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024NASDAQ:XERSXeris Biopharma Holdings Inc
30/05/202408:30Business WireXeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)NASDAQ:XERSXeris Biopharma Holdings Inc
30/05/202408:00Business WireXeris to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
09/05/202408:00Business WireXeris Biopharma Reports First Quarter 2024 Financial Results and Recent EventsNASDAQ:XERSXeris Biopharma Holdings Inc
06/05/202408:00Business WireXeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta BionicsNASDAQ:XERSXeris Biopharma Holdings Inc
02/05/202408:00Business WireXeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
03/04/202417:05Business WireXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:XERSXeris Biopharma Holdings Inc
02/04/202408:00Business WireXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202418:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202409:02Business WireXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent EventsNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202409:00Business WireXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin CapitalNASDAQ:XERSXeris Biopharma Holdings Inc
28/02/202409:00Business WireXeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
05/02/202409:00Business WireXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
10/01/202412:12Dow Jones NewsXeris Biopharma Shares Climb 12% on Amgen License AgreementNASDAQ:XERSXeris Biopharma Holdings Inc
10/01/202410:53Dow Jones NewsXeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease TreatmentNASDAQ:XERSXeris Biopharma Holdings Inc
10/01/202410:00Business WireXeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of TeprotumumabNASDAQ:XERSXeris Biopharma Holdings Inc
04/01/202409:00Business WireXeris Biopharma Updates Its Outlook for 2023NASDAQ:XERSXeris Biopharma Holdings Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:XERS

Seu Histórico Recente

LSE
UU71
Morg.st.b.v 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados